Govt GBRC Chemistry Recruitment 2020 - Application Details
Jobs

Govt GBRC Chemistry Recruitment 2020 – Application Details

Swarna Khushbu - 0
Syngene Freshers Pharma Research Vacancy 2020 - Apply Online
Jobs

Syngene Freshers Pharma Research Vacancy 2020 – Apply Online

Swarna Khushbu - 0
Remdesivir price in India
News

Cipla To Price Remdesivir For COVID-19 Under Rs 5,000

Namitha Thambi - 0
PhD Chemistry Principal Investigator Vacancy @ Syngene
Jobs

PhD Chemistry Principal Investigator Vacancy @ Syngene

Swarna Khushbu - 0
Freshers Chemist Job Vacancy PI Industries - Apply Online
Jobs

Freshers Chemist Job Vacancy PI Industries – Apply Online

Swarna Khushbu - 0
Freshers Chemistry Junior Executive Job Opening - Syngene
B.sc Chemistry

Freshers Chemistry Junior Executive Job Opening – Syngene

Swarna Khushbu - 1
Banaras Hindu University Pharmacist Job Opening 2020
Jobs

Banaras Hindu University Pharmacist Job Opening 2020

Swarna Khushbu - 0
JNU-SCMM Pharma Recruitment 2020 - Application Details
Jobs

JNU-SCMM Pharma Recruitment 2020 – Application Details

Swarna Khushbu - 0
Both the World Health Organization (WHO) and NIH’s National Heart, Lung, and Blood Institute (NHLBI) have halted hydroxychloroquine's clinical studies conducted to assess the safety and effectiveness of the drug to treat adults with Covid-19 and Novartis, due to its inability to recruit enough patients, ended the Phase III trials of the same drug. One week before, the FDA had revoked its emergency use authorization (EUA) for hydroxychloroquine due to a randomized controlled clinical trial that showed no clinical benefit and the lack of consistent replication of earlier promising results. A data and safety monitoring board (DSMB) found that hydroxychloroquine is not beneficial in treating COVID-19, compared to placebo. However, NIH noted that the drug is not harmful. DSMB recommended the National Heart, Lung, and Blood Institute (NHLBI) to halt the study after a fourth interim analysis.  The randomized, blinded, placebo-controlled clinical trial was conducted in more than 500 patients infected with the novel coronavirus, among which 470 were recruited at the time of trial’s closure. 400mg hydroxychloroquine was given twice a day to the participants for two doses, followed by 200mg twice daily for the next eight doses, or a placebo twice daily for five days. Meanwhile, Novartis, a Swiss pharmaceutical company suspended the phase III clinical trials of hydroxychloroquine, as the completion of the trial was infeasible due to enrollment challenges. No conclusions have been made on the efficacy of the drug in treating COVID-19 and no safety issues have been reported, the company noted. Due to the recruitment challenges, the clinical team was unable to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with Covid-19, said Novartis. However, Novartis will continue to supply HCQ upon government requests and for certain ongoing investigator-initiated trials (IITs). Since HCQ showed no benefit compared to standard of care in reducing deaths, the World Health Organization also halted the clinical trials of hydroxychloroquine on June 17. Source
News

NIH, WHO And Novartis Ended Hydroxychloroquine Trials For COVID-19

Namitha Thambi - 0
Drugs to Treat COVID19 In India Fabiflu, Covifor, Cipremi, and other drugs
News

COVID-19 Treatment In India: Drugs Approved or Under Trial for COVID-19...

Prathibha HC - 0
1...1,5741,5751,576...2,566Page 1,575 of 2,566